top of page
AAVizion.png

Advanced Guidance for Ocular Gene Therapy

Strategic, translational, and clinical insights for investors, startups, and academic groups

Developing an ocular AAV gene therapy program?

Get expert scientific and regulatory guidance
from preclinical strategy to IND readiness

Start with a free initial consultation

Our Expertise

Vector Design & Candidate Selection

AAV design.png

Optimize AAV vector design and identify strong clinical candidates

IND-Enabling Studies & GLP Toxicology

IND enabling and GLP tox studies.png

Design IND-enabling studies, efficacy models, biodistribution, and GLP toxicology

Functional Potency Assay Design

Functional assay.png

Develop functional potency assays that support translatinal and regulatory readiness

How we support our clients?

INvesters Icon.png

Investors

De-risk ocular gene therapy investments with scientific, regulatory, and CMC diligence

Startups Icon.png

Startups

Build a credible path from preclinical to IND readiness

Academic Icons.png

Academic Teams

Translate early science into a focused, development ready program

Why AAVizion

A unique blend of specialized ocular gene therapy expertise and long-standing ophthalmic drug discovery experience

ChatGPT Image Apr 24, 2026, 05_50_16 PM.png
Extensive Ocular Gene Therapy Expertise

Over two decades of experience in ocular gene therapy for inherited retinal conditions

Expert Vision

ChatGPT Image Apr 24, 2026, 05_51_02 PM.png
Broad Ocular Drug Discovery Expertise

Four decades of combined experience in ocular drug discovery spanning small molecules, biologics, and antibodies.

AAVision Methods

why_aavision_specialized_not_generalist_36e2768c (1).png
Eye-Centricity

Focused guidance tailored to ocular therapeutics and translational strategy, and development planning

bottom of page